Dumont & Blake Investment Advisors LLC Has $1.14 Million Stock Position in DaVita Inc. (NYSE:DVA)

Dumont & Blake Investment Advisors LLC grew its position in DaVita Inc. (NYSE:DVA) by 2.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 8,290 shares of the company’s stock after acquiring an additional 170 shares during the quarter. Dumont & Blake Investment Advisors LLC’s holdings in DaVita were worth $1,144,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. acquired a new position in DaVita in the fourth quarter worth approximately $30,000. Principal Securities Inc. bought a new position in shares of DaVita during the 4th quarter valued at $37,000. GAMMA Investing LLC acquired a new stake in shares of DaVita in the 4th quarter valued at $60,000. Quest Partners LLC bought a new stake in DaVita in the fourth quarter worth $74,000. Finally, Federated Hermes Inc. increased its position in DaVita by 1,284.4% during the third quarter. Federated Hermes Inc. now owns 1,246 shares of the company’s stock worth $118,000 after buying an additional 1,156 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DVA shares. Truist Financial upped their price target on DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th. Barclays lifted their price objective on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Monday, May 6th. Finally, StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, DaVita currently has an average rating of “Moderate Buy” and a consensus target price of $144.67.

Insider Activity at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the transaction, the director now directly owns 10,954 shares of the company’s stock, valued at approximately $1,520,524.74. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.00% of the stock is currently owned by insiders.

DaVita Stock Performance

Shares of DVA stock traded down $2.88 during mid-day trading on Friday, reaching $138.57. The stock had a trading volume of 932,041 shares, compared to its average volume of 1,010,052. The firm has a market cap of $12.15 billion, a PE ratio of 15.75, a P/E/G ratio of 1.06 and a beta of 0.96. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. DaVita Inc. has a one year low of $71.51 and a one year high of $147.93. The firm’s 50 day simple moving average is $139.71 and its 200 day simple moving average is $126.75.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The firm had revenue of $3.07 billion during the quarter, compared to analysts’ expectations of $3.03 billion. During the same period last year, the business earned $1.58 earnings per share. DaVita’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, analysts forecast that DaVita Inc. will post 9.62 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.